- Home
- GLOB vs HTFL Comparison
GLOB vs HTFL Comparison
Compare GLOB & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLOB | HTFL |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLOB | HTFL |
|---|---|---|
| Price | $50.90 | $32.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $77.13 | $38.20 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 05-14-2026 | 05-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.98 | $27.66 |
| Revenue Next Year | $5.18 | $23.55 |
| P/E Ratio | $22.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.77 | $20.13 |
| 52 Week High | $142.25 | $41.22 |
Technical Indicators
Market Signals| Indicator | GLOB | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 60.25 | 75.33 |
| Support Level | $41.92 | $32.09 |
| Resistance Level | $53.90 | $32.52 |
| Average True Range (ATR) | 2.19 | 1.59 |
| MACD | 0.82 | 0.60 |
| Stochastic Oscillator | 81.72 | 91.34 |
Price Performance
Historical ComparisonAbout GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.